Astrazeneca

News
Sobi

Did AZ scupper Sobi's $8bn private equity buyout?

An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take it back into private ownership has collapsed, with reports suggesting AstraZen